Cat. No.: DAB-0011834
Product Information | |
---|---|
Clonality | Monoclonal |
Host Species | Rabbit |
Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu265 of human Atg5 protein, a synthetic peptide corresponding to residues surrounding Ser36 of human Atg12 protein, a synthetic peptide corresponding to residues near the amino terminus of human Atg16L1 protein, and a synthetic peptide corresponding to residues near the amino terminus of human Atg7 protein. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Gene Description | Autophagy is a catabolic process for the autophagosomic-lysosomal degradation of bulk cytoplasmic contents. Autophagy is generally activated by conditions of nutrient deprivation but has also been associated with a number of physiological processes including development, differentiation, neurodegeneration, infection, and cancer. The molecular machinery of autophagy was largely discovered in yeast and referred to as autophagy-related genes. Formation of the autophagosome involves a ubiquitin-like conjugation system in which Atg12 is covalently bound to Atg5 and targeted to autophagosome vesicles. This conjugation reaction is mediated by the ubiquitin E1-like enzyme Atg7 and the E2-like enzyme Atg10. Atg16L1 binds Atg5 of the Atg12-Atg5 conjugate forming an 800 kDa multimeric complex. The Atg12-Atg-5-Atg16L1 complex localizes to pre-autophagosomal membranes where it determines the site of LC3 lipidation and catalyzes the reaction required for the formation of mature autophagosomes. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at +4 °C short term (1-2 weeks). Store at -20 °C long term. |
Storage Buffer | Constituent: 100% PBS |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.